Latest Period
Q2 2026
Security Snapshot
Aquestive Therapeutics, Inc. - Common Stock (AQST) Institutional Ownership
CUSIP: 03843E104
13F Institutional Holders and Ownership History from Q3 2018 to Q2 2026
Institutions Reporting
184
Shares (Excl. Options)
72,006,061
Price
$4.16
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- AQST on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 72,006,061
- Total 13F value
- $299,524,927
- Portfolio coverage rank
- 0%
- Share change
- +128,838
- Value change
- +$543,176
- Number of holders
- 184
- Shares outstanding
- 124,885,109
- SEC-reported price per share
- $3.73
- Insider filing price
- $3.73
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AQST - Aquestive Therapeutics, Inc. - Common Stock is tracked under CUSIP 03843E104.
- 184 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 179 to 184 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $297,983,220 to $299,524,927.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 184 institutions filings for Q2 2026.
Security key
03843E104
Latest holder period
Q2 2026
13F holders
184
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
AQST full holder history
Aquestive Therapeutics, Inc. SEC filings
Aquestive Therapeutics, Inc. company facts
Aquestive Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03843E104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
AQST
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BRATTON DOUGLAS K | 11% | $28,720,687 | 10,077,434 | BRATTON DOUGLAS K | 31 Dec 2024 | |||
| BlackRock, Inc. | 6.4% | +22% | $33,249,412 | +$6,515,825 | 7,992,647 | +24% | BlackRock, Inc. | 30 Jun 2026 |
| RTW INVESTMENTS, LP | 5.2% | $34,937,500 | 6,250,000 | RTW Investments, LP | 30 Sep 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 2.9% | $7,494,890 | 2,629,786 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2024 |
As of 30 Jun 2026, 184 institutional investors reported holding 72,006,061 shares of Aquestive Therapeutics, Inc. - Common Stock (AQST). This represents 58% of the company’s total 124,885,109 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
47%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Bratton Capital Management, L.P. | 7.9% | 9,810,958 | 0% | 100% | $40,813,585 |
| BlackRock, Inc. | 6.5% | 8,069,373 | +7.5% | 0% | $33,568,590 |
| RTW INVESTMENTS, LP | 5.9% | 7,426,471 | 0% | 0.26% | $30,894,119 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 4,584,533 | +3.2% | 0% | $19,071,657 |
| FEDERATED HERMES, INC. | 2.5% | 3,112,561 | +5.9% | 0.02% | $12,948,253 |
| STATE STREET CORP | 2.3% | 2,928,020 | +15% | 0% | $12,180,563 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 2,622,888 | +8.9% | 0% | $10,913,743 |
| SAMSARA BIOCAPITAL, LLC | 2% | 2,500,000 | 0% | 0.85% | $10,400,000 |
| BANK OF AMERICA CORP /DE/ | 1.3% | 1,668,423 | -31% | 0% | $6,940,640 |
| Sio Capital Management, LLC | 1.2% | 1,486,175 | -23% | 1.1% | $6,182,488 |
| Propel Bio Management, LLC | 1.2% | 1,442,397 | +103% | 3.1% | $6,000,372 |
| WASATCH ADVISORS LP | 1.1% | 1,385,843 | +58% | 0.04% | $5,765,107 |
| TWO SIGMA INVESTMENTS, LP | 1% | 1,281,227 | +12% | 0% | $5,329,904 |
| Nuveen, LLC | 0.97% | 1,215,225 | +379% | 0% | $5,055,336 |
| Janney Montgomery Scott LLC | 0.89% | 1,106,160 | +1.6% | 0.01% | $4,602,000 |
| WELLS FARGO & COMPANY/MN | 0.87% | 1,089,037 | +5.3% | 0% | $4,530,394 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.84% | 1,046,175 | -3.4% | 0.01% | $4,352,090 |
| BARCLAYS PLC | 0.8% | 996,665 | +25% | 0% | $4,146,126 |
| Blue Owl Capital Holdings LP | 0.76% | 942,932 | -30% | 0.6% | $3,922,597 |
| NORTHERN TRUST CORP | 0.67% | 831,151 | +13% | 0% | $3,457,589 |
| BNP PARIBAS FINANCIAL MARKETS | 0.64% | 794,688 | 0% | 0% | $3,305,902 |
| Balyasny Asset Management L.P. | 0.6% | 744,536 | -74% | 0.01% | $3,097,270 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.59% | 734,245 | +6.1% | 0% | $3,054,459 |
| MORGAN STANLEY | 0.53% | 658,617 | -59% | 0% | $2,739,848 |
| VANGUARD FIDUCIARY TRUST CO | 0.52% | 651,211 | +2.1% | 0% | $2,709,038 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
32
Latest
Q2 2026
Rows shown
1-25 of 32
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 72,006,061 | $299,524,927 | +$543,176 | $4.16 | 184 |
| 2026 Q1 | 71,802,682 | $297,983,220 | -$19,725,871 | $4.15 | 179 |
| 2025 Q4 | 72,216,999 | $466,378,990 | +$34,098,128 | $6.46 | 178 |
| 2025 Q3 | 66,072,635 | $369,385,999 | +$106,443,073 | $5.59 | 151 |
| 2025 Q2 | 47,601,655 | $157,593,347 | +$12,692,456 | $3.31 | 115 |
| 2025 Q1 | 44,051,858 | $127,751,552 | -$2,587,459 | $2.90 | 120 |
| 2024 Q4 | 43,378,481 | $154,428,036 | -$13,648,629 | $3.56 | 113 |
| 2024 Q3 | 46,754,842 | $232,438,651 | +$19,226,897 | $4.98 | 116 |
| 2024 Q2 | 42,397,820 | $110,236,742 | -$9,111,350 | $2.60 | 95 |
| 2024 Q1 | 41,491,141 | $176,751,489 | +$88,086,384 | $4.26 | 96 |
| 2023 Q4 | 23,788,793 | $48,053,747 | +$1,931,780 | $2.02 | 57 |
| 2023 Q3 | 13,082,950 | $20,018,501 | +$5,799,587 | $1.53 | 45 |
| 2023 Q2 | 19,076,504 | $31,486,971 | +$6,895,297 | $1.65 | 54 |
| 2023 Q1 | 14,936,175 | $17,026,675 | +$181,515 | $1.14 | 34 |
| 2022 Q4 | 14,914,775 | $13,452,963 | -$924,306 | $0.90 | 34 |
| 2022 Q3 | 15,885,912 | $18,581,000 | -$701,258 | $1.17 | 41 |
| 2022 Q2 | 16,697,754 | $10,681,727 | -$1,110,269 | $0.64 | 37 |
| 2022 Q1 | 15,540,728 | $40,562,854 | -$1,905,712 | $2.61 | 49 |
| 2021 Q4 | 16,159,821 | $62,860,046 | +$1,542,125 | $3.89 | 50 |
| 2021 Q3 | 14,777,244 | $64,430,510 | -$3,394,828 | $4.36 | 44 |
| 2021 Q2 | 15,624,060 | $62,031,877 | -$6,395,474 | $3.97 | 56 |
| 2021 Q1 | 16,607,064 | $86,353,974 | -$13,347,120 | $5.20 | 62 |
| 2020 Q4 | 19,140,719 | $102,400,992 | -$3,894,598 | $5.35 | 65 |
| 2020 Q3 | 19,883,853 | $96,529,634 | +$6,732,727 | $4.85 | 57 |
| 2020 Q2 | 18,511,676 | $89,959,616 | +$16,355,927 | $4.86 | 56 |